Toxoplasmosis Infection Treatment Market

Toxoplasmosis Infection Treatment Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment; 2017 – 2027

  • Ongoing
  • September 2020
  • REP-GB-4923
  • Format: PDF/PPT/Excel
  • SELECT LICENSE TYPE :

  • US$5,000
  • US$7,500
  • US$10,000

This Toxoplasmosis Infection Treatment market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Toxoplasmosis Infection Treatment market.

Toxoplasmosis caused by a single celled parasite called “Toxoplasma gondii”, which results in an infection usually occurs by raw or undercooked contaminated meat particularly lamb or pork, drinking contaminated water and milk from an infected goat, exposure from cat feces, mother to child transmission during pregnancy and organs transplantation in rare cases.

Toxoplasmosis Infections causes flu like symptoms including muscle ache, body ache, fever, headache, sore throat, fatigue, swollen lymph nodes and swollen glands etc. People with weakened immune system develop more severe signs of infection and inflammation including brain inflammation, lung infection, poor coordination and blurred vision and eye infection.

Some factors including HIV/AIDS positive individuals, or undergoing chemotherapy patients and pregnant ladies having a risk of serious health problems. Medication for HIV/AIDS positive individuals, consist pyrimethamine and sulfadiazine, with folinic acid (leucovorin) given on the treatment choice. Pyrimethamine with clindamycin (Cleocin) used as an alternative source. Sulfadiazine, which is an antibiotic used in combination with pyrimethamine to treat toxoplasmosis. During pregnancy, if the infection occurred after the 16th week, spiramycin (antibiotic) recommended in the first three months or in the second early trimester to treat the infection that reduces the risk of neurological problems in the baby. The combination of sulfadoxine with pyrimethamine is also used to prevent certain types of malaria. The treatment of toxoplasmosis includes a blood test to check the presence of antibodies of the related parasite.

Doctors typically prescribe medication consist antibiotic to treat the infection. The medication is depending on eye lesion size, type of the lesion (acute active, versus chronic not progressing) and the location of the infection.

  • Identify Key Market Forces and their Long-Term Forecast
  • Sneak Peek into Key Forecast Factors and thier Impact

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

Toxoplasmosis Infection Treatment Market: Drivers and Restrains

The toxoplasmosis infection treatment market is expected to be driven by the rising health awareness, high incidences of foodborne illness. With the increasing incidence of toxoplasmosis, and high investment in toxoplasmosis research, the market is expected to grow during the forecast period. However, certain side effects of high dosage drugs that includes blood disorders, allergic reactions, tongue changes and anorexia etc are posing a restrain to toxoplasmosis infection treatment market.

Toxoplasmosis Infection Treatment Market: Overview

The toxoplasmosis infection treatment market is expected to growth at a healthy growth rate during the forecast period. This is due to high incidence of Toxoplasmosis, an infectious disease caused by a protozoan. Government initiatives to prevent risk of toxoplasmosis and other infection from food is expected to drive the market during the forecast years.

Toxoplasmosis Infection Treatment Market: Regional overview

Region wise, the global toxoplasmosis infection treatment market is classified into seven regions namely North America, Latin America, Eastern Europe, Western Europe, Japan, Asia-Pacific excluding Japan, Middle East and Africa. North America is expected to hold the highest market share with strong growth of pyrimethamine treatment market. Better government initiatives to educate people on the prevention of toxoplasmosis would reduce risk in the environment and open more business opportunities for research and development. The second largest market hold by Europe market followed by Asia pacific excluding Japan.

Toxoplasmosis Infection Treatment Market: Key Players

Some of the major players in toxoplasmosis infection treatment market include Impax Laboratories Inc., Turing Pharmaceuticals, Lupin Limited, Amneal Pharmaceuticals, Turing pharmaceuticals LLC, Pharmaceuticals LLC, Novartis International AG, F. Hoffmann-La Roche AG., Gilead Sciences, Greenstone LLC and others.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Toxoplasmosis Infection Treatment Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Toxoplasmosis Infection Treatment Market: Segmentation

The global toxoplasmosis infection treatment market is classified on the drug type and the distribution channel.

Global Toxoplasmosis Infection Treatment Market, by drugs type-

  • Pyrimethamine Combination
  • Sulfadiazine Combination
  • Leucovorin Combination (Folinic acid)
  • Spiramycin Combination
  • Clindamycin Combination
  • Atovaquone Combination

Global Toxoplasmosis Infection Treatment Market, by distribution channel-

  • Hospital Pharmacies
  • Drug stores
  • Retail pharmacy
  • E-commerce
  • Others

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Toxoplasmosis Infection Treatment Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Toxoplasmosis Infection Treatment Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch

Harish Tiwari

Global Head - Business Development

Akshay Godge

Client Partner - Global Business Development

Our Clients


Request Sample Request customization Request Methodology